Amino acid substitution mutants of interleukin 13
US6630576B2 · kind B2 · utility
17Cited by
3References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 24, 2001 |
| Grant date | Oct 7, 2003 |
| Priority date | — |
| Expiry date | Aug 24, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides mutant hIL13 molecules include those made by substituting one or more of the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Multiply mutated forms of hIL13 conjugated to cytotoxins are used to preferentially target diseased cells over non-diseased cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.